Malawi

in page functions
[French]
Malawi
Total population (2017) 18,298,666
Birth cohort (2017) 692,291
Surviving Infants (surviving to 1 year per year, 2017) 656,296
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 43/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 64/1000
World Bank Index, IDA (2015) 3.15
Gross Nation Income (per capita US$, 2015) 340
Co-financing group (2017) Initial self-financing
No. of districts/territories (2015) 28

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Malawi

Type of support

Approvals

2001-2021 (US$)
(25 Apr 2017)

Commitments

2001-2021 (US$)
(25 Apr 2017)

Disbursements

2000-2017 (US$)
(25 Apr 2017)

% Disbursed

(25 Apr 2017)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Total $202,026,593 $244,284,093 $201,637,744
Cash Support (CASHSUPP) $197,000 $197,000 $172,000 87%
Health system strengthening (HSS 1) $11,002,375 $11,002,375 $11,002,375 100%
Health system strengthening (HSS 2) N/A
HPV Demo (NVS) $475,773 $475,773 $477,595 100%
Immunisation services support (ISS) $1,986,000 $1,986,000 $1,986,000 100%
Injection Safety Devices (NVS) $313,000 $1,064,000 $384,225 123%
Injection safety support (INS) $722,509 $722,509 $722,509 100%
IPV (NVS) $75,039 $75,039 $57,964 77%
Measles (NVS) $659,215 $659,215 $669,223 102%
Measles-Rubella (NVS) $6,410,000 $6,410,000 $6,490,140 101%
MR - Operational costs (OPC) $5,030,349 $5,030,349 $5,030,349 100%
Penta (NVS) $91,253,569 $98,865,069 $89,422,178 98%
Pneumo (NVS) $65,147,342 $89,672,842 $67,667,380 104%
Product Switch Grant (PSG) $182,500 $182,500
Rotavirus (NVS) $15,967,433 $25,336,933 $14,951,317 94%
Vaccine Introduction Grant (VIG) $2,604,489 $2,604,489 $2,604,489 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Malawi DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2015)

Grade of confidence


N/A
DTP3 - Official country estimates (2015) 88%
M:F sex ratio at birth (2017) 1.03
Household survey: DTP3 coverage for male (2013) 92.30%
Household survey: DTP3 coverage for female (2013) 92.90%
Household survey: Last DTP3 survey (2013) 93%
% districts achieving > 80% DTP3 coverage (2015) 75%
% districts achieving < 50% DTP3 coverage (2015) 0%
MCV WHO/UNICEF estimates (2015) 87%

Breakdown of support

Non-vaccine support Vaccine support
11% 89%
$21,517,722 $180,120,022

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Malawi

23 May 2017

Seth Q&A

Big Ideas: Gavi CEO Seth Berkley’s Q&A, Part II

Ahead of Seth Berkley’s speech to the 2017 graduating class at Johns Hopkins University in Washington, DC on 23 June, Global Health published a two-part Q&A with the Gavi CEO. In this second article, Seth shares his concerns about the expansion of the vaccine hesitancy movement, explains why digital identity technologies in low- and middle-income countries can help improve vaccine coverage, and discusses the value of testing the potentially important malaria vaccine.

24 April 2017

Mosquito malaria

Partnership supports launch of malaria vaccine pilots in three African countries

Funders hail next step in the development of world’s first malaria vaccine.

01 December 2015

Dagfinn Høybråten in Geneva 2015

'Deliver, deliver, deliver' – Dagfinn Høybråten reflects on five years as Gavi Board Chair

Dagfinn Høybråten will this week chair a Gavi Board meeting for the last time before stepping down at the end of the year. Here he reflects on five years at the helm of the Vaccine Alliance, steering Gavi through some of the momentous events in its 15-year history.

close icon

modal window here